Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases

Abstract A large number of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies, immune cells have been recognized as key players contributing to atherosclerotic plaque progression and destabilization. Particularly the role of innate immune cells is of major interest, following the recent paradigm shift that innate immunity, long considered to be incapable of learning, does exhibit immunological memory mediated via epigenetic reprogramming. Compelling evidence shows that atherosclerotic risk factors promote immune cell migration by pre-activation of circulating innate immune cells. Innate immune cell activation via metabolic and epigenetic reprogramming perpetuates a systemic low-grade inflammatory state in cardiovascular disease (CVD) that is also common in other chronic inflammatory disorders. This opens a new therapeutic area in which metabolic or epigenetic modulation of innate immune cells may result in decreased systemic chronic inflammation, alleviating CVD, and its co-morbidities.

[1]  L. Joosten,et al.  Specific and Complex Reprogramming of Cellular Metabolism in Myeloid Cells during Innate Immune Responses. , 2017, Cell metabolism.

[2]  S. Gabriel,et al.  Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease , 2017, The New England journal of medicine.

[3]  L. O’Neill,et al.  Macrophage Immunometabolism: Where Are We (Going)? , 2017, Trends in immunology.

[4]  G. Fredman,et al.  Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. , 2017, The American journal of pathology.

[5]  E. Stroes,et al.  PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia , 2017, European heart journal.

[6]  C. Voermans,et al.  Remnant Cholesterol Elicits Arterial Wall Inflammation and a Multilevel Cellular Immune Response in Humans , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[7]  A. Blom,et al.  S100A8/A9 increases the mobilization of Ly6C high monocytes to the synovium during experimental osteoarthritis , 2017 .

[8]  A. El-Osta,et al.  Metabolism and chromatin dynamics in health and disease. , 2017, Molecular aspects of medicine.

[9]  A. Murphy,et al.  Effects of dyslipidaemia on monocyte production and function in cardiovascular disease , 2017, Nature Reviews Cardiology.

[10]  Matthew A. Cooper,et al.  Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice , 2017, Science.

[11]  Richard A. Notebaart,et al.  Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity. , 2016, Cell metabolism.

[12]  M. Oosting,et al.  Immunometabolic Pathways in BCG-Induced Trained Immunity , 2016, Cell reports.

[13]  M. D. de Winther,et al.  Epigenetic Regulation of Monocyte and Macrophage Function. , 2016, Antioxidants & redox signaling.

[14]  L. Joosten,et al.  Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo. , 2016, Atherosclerosis.

[15]  L. Joosten,et al.  In Vitro Experimental Model of Trained Innate Immunity in Human Primary Monocytes , 2016, Clinical and Vaccine Immunology.

[16]  L. Joosten,et al.  Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans , 2016, Circulation.

[17]  E. Latz,et al.  Long-term activation of the innate immune system in atherosclerosis. , 2016, Seminars in immunology.

[18]  C. Voermans,et al.  Increased haematopoietic activity in patients with atherosclerosis , 2016, European heart journal.

[19]  J. Rudd,et al.  Imaging unstable plaque. , 2016, The Quarterly Journal of Nuclear Medicine and Molecular Imaging.

[20]  E. Stroes,et al.  Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study , 2016, Arthritis Research & Therapy.

[21]  R. Xavier,et al.  Trained immunity: A program of innate immune memory in health and disease , 2016, Science.

[22]  A. Tall,et al.  Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming , 2016, Science Translational Medicine.

[23]  P. Young,et al.  RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease. , 2016, Atherosclerosis.

[24]  M. Nahrendorf,et al.  Innate immune cells in ischaemic heart disease: does myocardial infarction beget myocardial infarction? , 2016, European heart journal.

[25]  T. Assimes,et al.  The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease , 2016, The Journal of experimental medicine.

[26]  J. Sandelin,et al.  Soluble biglycan: a potential mediator of cartilage degradation in osteoarthritis , 2015, Arthritis Research & Therapy.

[27]  K. Moore,et al.  MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis. , 2015, The Journal of clinical investigation.

[28]  M. D. de Winther,et al.  Epigenetic pathways in macrophages emerge as novel targets in atherosclerosis. , 2015, European journal of pharmacology.

[29]  A. Jaworowski,et al.  Inflammation‐induced foam cell formation in chronic inflammatory disease , 2015, Immunology and cell biology.

[30]  M. Nicklaus,et al.  Metabolic Regulation of Histone Acetyltransferases by Endogenous Acyl-CoA Cofactors. , 2015, Chemistry & biology.

[31]  L. Joosten,et al.  The epigenetic memory of monocytes and macrophages as a novel drug target in atherosclerosis. , 2015, Clinical therapeutics.

[32]  P. Camici,et al.  Non-invasive molecular imaging of vulnerable atherosclerotic plaques. , 2015, Journal of cardiology.

[33]  N. van Bruggen,et al.  FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. , 2015, JACC. Cardiovascular imaging.

[34]  A. Mangoni,et al.  The Impact of Traditional Cardiovascular Risk Factors on Cardiovascular Outcomes in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis , 2015, PloS one.

[35]  A. El-Osta,et al.  Epigenetics and metabolism. , 2015, Circulation research.

[36]  C. Glass,et al.  The selection and function of cell type-specific enhancers , 2015, Nature Reviews Molecular Cell Biology.

[37]  J. Min,et al.  Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. , 2015, JACC. Cardiovascular imaging.

[38]  J. Rudd,et al.  Techniques for noninvasive molecular imaging of atherosclerotic plaque , 2015, Nature Reviews Cardiology.

[39]  M. Moskowitz,et al.  Ischemic Stroke Activates Hematopoietic Bone Marrow Stem Cells , 2015, Circulation research.

[40]  A. Tall,et al.  Cholesterol, inflammation and innate immunity , 2015, Nature Reviews Immunology.

[41]  P. Libby,et al.  Inflammation and Immunity in Diseases of the Arterial Tree: Players and Layers , 2015, Circulation research.

[42]  E. Latz,et al.  Danger signaling in atherosclerosis. , 2015, Circulation research.

[43]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[44]  P. Tak,et al.  The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts , 2014, Annals of the rheumatic diseases.

[45]  P. Libby,et al.  Increased Microvascularization and Vessel Permeability Associate With Active Inflammation in Human Atheromata , 2014, Circulation. Cardiovascular imaging.

[46]  Andrew L. Kung,et al.  NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. , 2014, Molecular cell.

[47]  Diederik F Van Wijk,et al.  Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia. , 2014, Journal of the American College of Cardiology.

[48]  R. Xavier,et al.  mTOR- and HIF-1α–mediated aerobic glycolysis as metabolic basis for trained immunity , 2014, Science.

[49]  Z. Fayad,et al.  In vivo imaging of enhanced leukocyte accumulation in atherosclerotic lesions in humans. , 2014, Journal of the American College of Cardiology.

[50]  P. Young,et al.  A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. , 2014, Atherosclerosis.

[51]  F. Bengel,et al.  Characterizing the Inflammatory Tissue Response to Acute Myocardial Infarction by Clinical Multimodality Noninvasive Imaging , 2014, Circulation. Cardiovascular imaging.

[52]  J. Repa,et al.  Histone Deacetylase 9 Represses Cholesterol Efflux and Alternatively Activated Macrophages in Atherosclerosis Development , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[53]  P. Tak,et al.  From Synovial Tissue to Peripheral Blood: Myeloid Related Protein 8/14 Is a Sensitive Biomarker for Effective Treatment in Early Drug Development in Patients with Rheumatoid Arthritis , 2014, PloS one.

[54]  L. Joosten,et al.  Oxidized Low-Density Lipoprotein Induces Long-Term Proinflammatory Cytokine Production and Foam Cell Formation via Epigenetic Reprogramming of Monocytes , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[55]  M. Netea,et al.  Innate immune memory: towards a better understanding of host defense mechanisms. , 2014, Current opinion in immunology.

[56]  Paul M Ridker,et al.  Anti-inflammatory therapies for cardiovascular disease. , 2014, European heart journal.

[57]  C. Glass,et al.  Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions , 2014, EMBO molecular medicine.

[58]  Ira Tabas,et al.  Inflammation and its Resolution as Determinants of Acute Coronary Syndromes , 2014, Circulation research.

[59]  Trees Jansen,et al.  Trained Immunity or Tolerance: Opposing Functional Programs Induced in Human Monocytes after Engagement of Various Pattern Recognition Receptors , 2014, Clinical and Vaccine Immunology.

[60]  Z. Fayad,et al.  Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging. , 2014, Journal of the American College of Cardiology.

[61]  P. Carmeliet,et al.  Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. , 2014, Cell metabolism.

[62]  Y. Momiyama,et al.  Inflammation, Atherosclerosis and Coronary Artery Disease , 2014, Clinical Medicine Insights. Cardiology.

[63]  T. Brady,et al.  Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. , 2013, JACC. Cardiovascular imaging.

[64]  L. Joosten,et al.  Trained innate immunity and atherosclerosis , 2013, Current opinion in lipidology.

[65]  R. Xavier,et al.  Long-Lasting Effects of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity , 2013, Journal of Innate Immunity.

[66]  Z. Fayad,et al.  Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. , 2013, Journal of the American College of Cardiology.

[67]  D. Patel,et al.  Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases , 2013, Quarterly Reviews of Biophysics.

[68]  P. Libby,et al.  Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. , 2013, American heart journal.

[69]  P. Libby,et al.  Local proliferation dominates lesional macrophage accumulation in atherosclerosis , 2013, Nature Medicine.

[70]  Diederik F Van Wijk,et al.  ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. , 2013, European heart journal.

[71]  M. Nahrendorf,et al.  Leukocyte Behavior in Atherosclerosis, Myocardial Infarction, and Heart Failure , 2013, Science.

[72]  Ira Tabas,et al.  Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities , 2013, Science.

[73]  C. Nicchitta,et al.  Glycoprotein 96 perpetuates the persistent inflammation of rheumatoid arthritis. , 2012, Arthritis and rheumatism.

[74]  R. Xavier,et al.  Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes , 2012, Proceedings of the National Academy of Sciences.

[75]  E. Seifried,et al.  Acute myocardial infarction activates progenitor cells and increases Wnt signalling in the bone marrow. , 2012, European heart journal.

[76]  S. Abbara,et al.  Arterial inflammation in patients with HIV. , 2012, JAMA.

[77]  D. Pisetsky The origin and properties of extracellular DNA: from PAMP to DAMP. , 2012, Clinical immunology.

[78]  R. Gay,et al.  Increased recycling of polyamines is associated with global DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. , 2012, Arthritis and rheumatism.

[79]  Charles P. Lin,et al.  Myocardial infarction accelerates atherosclerosis , 2012, Nature.

[80]  Eoin Kavanagh,et al.  Carotid plaque inflammation on 18F‐fluorodeoxyglucose positron emission tomography predicts early stroke recurrence , 2012, Annals of neurology.

[81]  M. Rossol,et al.  "Pain and fatigue in adult patients with rheumatoid arthritis : association with demographic factors, disease related factors, body awareness, emotional and psychosocial factors" , 2012 .

[82]  P. Libby,et al.  Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis , 2012, The Journal of experimental medicine.

[83]  Ahmed Tawakol,et al.  Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial , 2011, The Lancet.

[84]  R. Dierckx,et al.  High-resolution imaging of human atherosclerotic carotid plaques with micro18F-FDG PET scanning exploring plaque vulnerability , 2011, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[85]  P. Libby,et al.  Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). , 2011, American heart journal.

[86]  T. Lüscher,et al.  Myeloid related proteins activate Toll-like receptor 4 in human acute coronary syndromes. , 2011, Atherosclerosis.

[87]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[88]  M. Netea,et al.  Trained immunity: a memory for innate host defense. , 2011, Cell host & microbe.

[89]  K. Moore,et al.  Macrophages in the Pathogenesis of Atherosclerosis , 2011, Cell.

[90]  A. Tedgui,et al.  Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets , 2011, Nature Reviews Cardiology.

[91]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[92]  Mary G. George,et al.  Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2011, Circulation.

[93]  Soo-Ho Choi,et al.  Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity , 2011, Circulation research.

[94]  Peter A. Jones,et al.  Epigenetic Modifications as Therapeutic Targets , 2010, Nature Biotechnology.

[95]  F. Eberli,et al.  Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes. , 2010, European heart journal.

[96]  G. Paulsson-Berne,et al.  Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis , 2010, The Journal of experimental medicine.

[97]  M. Chiariello,et al.  Leukocyte count in peripheral arterial disease: A simple, reliable, inexpensive approach to cardiovascular risk prediction. , 2010, Atherosclerosis.

[98]  F. Geissmann,et al.  Monocytes in atherosclerosis: subsets and functions , 2010, Nature Reviews Cardiology.

[99]  A. Zwinderman,et al.  Simvastatin with or without ezetimibe in familial hypercholesterolemia. , 2008, The New England journal of medicine.

[100]  A. Tall,et al.  HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. , 2008, Cell metabolism.

[101]  A. Dueñas-González,et al.  Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. , 2008, Cancer treatment reviews.

[102]  Marc Faraggi,et al.  Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events , 2008, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[103]  R. Pope,et al.  Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[104]  A. Sudo,et al.  Expression of large tenascin‐C splice variants in synovial fluid of patients with rheumatoid arthritis , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[105]  K. He,et al.  Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma , 2007, Clinical Cancer Research.

[106]  T. Giese,et al.  Pharmacodynamic Monitoring of Cyclosporine A in Renal Allograft Recipients Shows a Quantitative Relationship Between Immunosuppression and the Occurrence of Recurrent Infections and Malignancies , 2006, Transplantation.

[107]  K. Pavelka,et al.  S100A4 is expressed at site of invasion in rheumatoid arthritis synovium and modulates production of matrix metalloproteinases , 2006, Annals of the rheumatic diseases.

[108]  Ahmed Tawakol,et al.  In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. , 2006, Journal of the American College of Cardiology.

[109]  Martin J Graves,et al.  Identification of Culprit Lesions After Transient Ischemic Attack by Combined 18F Fluorodeoxyglucose Positron-Emission Tomography and High-Resolution Magnetic Resonance Imaging , 2005, Stroke.

[110]  Y. Kochi,et al.  Citrullination of fibronectin in rheumatoid arthritis synovial tissue. , 2005, Rheumatology.

[111]  Nina Singh,et al.  Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens , 2005, Current opinion in infectious diseases.

[112]  Joachim Kurtz,et al.  Specific memory within innate immune systems. , 2005, Trends in immunology.

[113]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[114]  Imran Awan,et al.  Leukocyte count and coronary heart disease: implications for risk assessment. , 2004, Journal of the American College of Cardiology.

[115]  P. Libby Inflammation in atherosclerosis , 2002, Nature.

[116]  Jun Yu Li,et al.  High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. , 2002, Arthritis and rheumatism.

[117]  J. Pickard,et al.  Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography , 2002, Circulation.

[118]  G. Hansson,et al.  Expression of Toll-Like Receptors in Human Atherosclerotic Lesions: A Possible Pathway for Plaque Activation , 2002, Circulation.

[119]  R. Medzhitov,et al.  Innate immune recognition: mechanisms and pathways , 2000, Immunological reviews.

[120]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[121]  G. Fredman,et al.  Boosting Inflammation Resolution in Atherosclerosis , 2017 .

[122]  M. Rossol,et al.  The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. , 2012, Arthritis and rheumatism.

[123]  I. Tabas Macrophage death and defective inflammation resolution in atherosclerosis , 2010, Nature Reviews Immunology.

[124]  John Andersson,et al.  Adaptive immunity and atherosclerosis. , 2010, Clinical immunology.

[125]  P. Ducimetiere,et al.  Monocyte count: a risk factor for coronary heart disease? , 1993, American journal of epidemiology.